Bank Of New York Mellon Corp Amicus Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

$538 Trillion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$10.91 - $13.54 $12.8 Million - $15.9 Million	1,171,355 New	1,171,355 $13 Billion
Q4 2022 Feb 14, 2023	BUY	$9.89 - $12.7 $11.8 Million - $15.1 Million	1,191,873 New	1,191,873 $14.6 Million
Q3 2022 Nov 14, 2022	BUY	$9.82 - $12.75 $548,329 - $711,934	55,838 Added 4.76%	1,229,564 $12.8 Million
Q2 2022 Aug 15, 2022	BUY	$6.23 - $11.12 $275,503 - $491,748	44,222 Added 3.92%	1,173,726 $12.6 Million
Q1 2022 May 11, 2022	BUY	$7.89 - $12.48 $15,669 - $24,785	1,986 Added 0.18%	1,129,504 $10.7 Million
Q4 2021 Feb 11, 2022	BUY	$9.82 - $12.44 $75,024 - $95,041	7,640 Added 0.68%	1,127,518 $13 Million
Q3 2021 Nov 12, 2021	BUY	$8.74 - $11.84 $142,339 - $192,826	16,286 Added 1.48%	1,119,878 $10.7 Million
Q2 2021 Aug 11, 2021	BUY	$8.71 - $10.72 $491,487 - $604,908	56,428 Added 5.39%	1,103,592 $10.6 Million
Q1 2021 May 13, 2021	SELL	$9.2 - $23.86 $12.5 Million - $32.4 Million	-1,357,320 Reduced 56.45%	1,047,164 $10.3 Million
Q4 2020 Feb 09, 2021	BUY	$13.47 - $24.89 $1.88 Million - $3.47 Million	139,270 Added 6.15%	2,404,484 $55.5 Million
Q3 2020 Nov 12, 2020	SELL	$12.89 - $15.89 $147,886 - $182,305	-11,473 Reduced 0.5%	2,265,214 $32 Million
Q2 2020 Aug 12, 2020	BUY	$8.86 - $15.69 $707,329 - $1.25 Million	79,834 Added 3.63%	2,276,687 $34.3 Million
Q1 2020 May 06, 2020	SELL	$6.63 - $11.16 $386,051 - $649,824	-58,228 Reduced 2.58%	2,196,853 $20.3 Million
Q4 2019 Feb 14, 2020	BUY	$7.48 - $10.75 $588,825 - $846,240	78,720 Added 3.62%	2,255,081 $22 Million
Q3 2019 Nov 07, 2019	BUY	$8.02 - $13.25 $342,742 - $566,252	42,736 Added 2.0%	2,176,361 $17.5 Million
Q2 2019 Aug 12, 2019	BUY	$10.96 - $14.4 $1.17 Million - $1.53 Million	106,532 Added 5.26%	2,133,625 $26.6 Million
Q1 2019 May 14, 2019	SELL	$10.04 - $13.92 $323,890 - $449,059	-32,260 Reduced 1.57%	2,027,093 $27.6 Million
Q4 2018 Feb 11, 2019	BUY	$8.38 - $13.44 $159,220 - $255,360	19,000 Added 0.93%	2,059,353 $19.7 Million
Q3 2018 Nov 09, 2018	SELL	$11.6 - $16.54 $74,414 - $106,104	-6,415 Reduced 0.31%	2,040,353 $0
Q2 2018 Aug 06, 2018	BUY	$13.13 - $17.09 $91,004 - $118,450	6,931 Added 0.34%	2,046,768 $32 Million
Q1 2018 May 15, 2018	BUY	$13.76 - $17.12 $16 Million - $19.9 Million	1,160,301 Added 131.92%	2,039,837 $30.7 Million
Q4 2017 Feb 09, 2018	BUY	$12.51 - $16.24 $11 Million - $14.3 Million	879,536	879,536 $12.7 Million

Others Institutions Holding FOLD

# of Institutions

311

Shares Held

312M

Call Options Held

516K

Put Options Held

833K

Vanguard Group Inc Valley Forge, PA

28.8M
Shares

$276 Million
0.01% of portfolio
Perceptive Advisors LLC New York, NY

28.1M
Shares

$269 Million
7.83% of portfolio
Black Rock Inc. New York, NY

24.4M
Shares

$233 Million
0.01% of portfolio
Wellington Management Group LLP Boston, MA

24M
Shares

$230 Million
0.05% of portfolio
Avoro Capital Advisors LLC New York, NY

23.2M
Shares

$222 Million
3.72% of portfolio

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.69B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account